3 terminated. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Kronos Bio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML Entospletinib, Placebo, Cytarabine - Nucleophosmin 1-mutated Acute Myeloid Leukemia | Phase 3 | Terminated | Kronos Bio | 15 | 2021-11-24 | 2024-01-10 |
| A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) KB-0742 - Relapsed Solid Tumors, Refractory Solid Tumors | Phase 1 / Phase 2 | Terminated | Kronos Bio | 135 | 2021-02-08 | 2025-02-17 |
Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (1)
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Anthracyclines (1) · Cytarabine (1) · gilteritinib (1)
Spain (3) · United States (3) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · United Kingdom (1)
2023 (1)